Jade Biosciences, Inc.
JBIODrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Aug 12, 2026
7dMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
JBIO Earnings Report
EPS Est: $-0.66 | FQ end 2026-06
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How JBIO's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
JADE101 | Phase 2 | IgA Nephropathy | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Jade Biosciences, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Jade Biosciences, Inc.'s (JBIO) pipeline across Phase 2. Its lead program is JADE101 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Jade Biosciences, Inc.'s next FDA catalyst?→
Jade Biosciences, Inc.'s (JBIO) next tracked catalyst is a Earnings expected August 12, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track JBIO biotech catalysts?→
Add JBIO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Jade Biosciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.